This content is in French.
Will biomarkers save patients with refractory testicular germ cell tumors?
1 décembre 2025
By Lila Rouland | Published on December 1rst, 2025 | 3 min readMetastatic testicular germ cell tumors (TGCTs) currently achieve high cure rates with cisplatin-based chemotherapy; however, 20–30% of patients relapse or exhibit resistance to first-line treatment. For those facing refractory or relapsed disease, the identification of prognostic and predictive biomarkers is becoming essential to optim
By Lila Rouland | Published on December 1rst, 2025 | 3 min read
Metastatic testicular germ cell tumors (TGCTs) currently achieve high cure rates with cisplatin-based chemotherapy; however, 20–30% of patients relapse or exhibit resistance to first-line treatment. For those facing refractory or relapsed disease, the identification of prognostic and predictive biomarkers is becoming essential to optimize salvage strategies, including conventional chemotherapy or high-dose regimens followed by autologous stem-cell transplantation.
Metastatic testicular germ cell tumors (TGCTs) currently achieve high cure rates with cisplatin-based chemotherapy; however, 20–30% of patients relapse or exhibit resistance to first-line treatment. For those facing refractory or relapsed disease, the identification of prognostic and predictive biomarkers is becoming essential to optimize salvage strategies, including conventional chemotherapy or high-dose regimens followed by autologous stem-cell transplantation.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Urbini, M., et al. (2023). Biomarkers for salvage therapy in testicular germ cell tumors. International Journal of Molecular Sciences, 24(23), 16872.
View the source
